



## **ACARIX RECEIVES BREAKTHROUGH ORDER FROM US VETERANS HEALTH ADMINISTRATION**

**Acarix, a leader in acoustic and AI-based cardiac diagnostics, announces today the first order from the US Veterans Health Administration (VA) consisting of 11 CADScor®Systems and 220 single-use patches. This order constitutes a breakthrough order with an initial value of SEK 1.0 million and with immediate delivery to the VA Southeast Louisiana Healthcare System.**

The Veterans Health Administration is the largest integrated health care system in the US with more than 350,000 employees. The VA provides care for over 9 million enrolled US veterans each year at 171 hospitals and over 1,000 outpatient clinics.

“This initial order from the US Veterans Health Administration is the result of a well-defined strategy focusing on key reference customers. Not only does it open doors into the large VA health care system, but it also validates how well the CADScor System fits into the US health care system, which is also changing in favor of technologies that can contribute to early assessment and diagnosis. The long-term value of this initial order is in the recurring sales of one-time patches”, said Helen Ljungdahl Round, President and CEO of Acarix.

The VA Southeast Louisiana Healthcare System provides healthcare services at 8 locations in southeast Louisiana. Facilities include the New Orleans VA Medical Center and eight community-based outpatient clinics in Baton Rouge, Bogalusa, Franklin, Hammond, Houma, Slidell, St. John Parish, and Baton Rouge South.

### **About Acarix**

Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor System uses advanced acoustics and AI-technology to rule out CAD non-invasively in less than 10 minutes, with at least 96% certainty. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, [certifiedadviser@redeye.se](mailto:certifiedadviser@redeye.se)) is Certified Advisor of Acarix. For more information, please visit [www.acarix.com](http://www.acarix.com).

### **For more information contact:**

Helen Ljungdahl Round, CEO, phone +1 267 809 1225, +46 730 770283, email [helen.round@acarix.com](mailto:helen.round@acarix.com)

Christian Lindholm, CFO, phone +46 705 118333, email [christian.lindholm@acarix.com](mailto:christian.lindholm@acarix.com)

*This information is information that Acarix is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-02-21 16:41 CET.*

21 February 2023 16:41:00 CET



**Attachments**

[Acarix receives breakthrough order from US Veterans Health Administration](#)